Search
forLearn
5 / 801 resultslearn LHA™
learn Folligen Complex
learn Folligen Black Effect Complex
learn fleece-flower
Research
5 / 1000+ results
research Mesotherapy with dutasteride and minoxidil in treatment of androgenetic alopecia
Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.
research 안드로겐성 탈모증의 치료에 따른 앞머리선의 변화
Using finasteride and minoxidil together improves the frontal hairline best in male hair loss.
research 원저 : 안드로겐성 탈모증의 치료에 따른 앞머리선의 변화
Using finasteride and minoxidil together improves the frontal hairline best in male hair loss.
research Female pattern hair loss
FPHL is a common, age-related, genetic hair loss with unclear causes and limited treatment options.
research Pharmacology of anabolic steroids
Anabolic steroids can build muscle and strength but have risks and need more research on their clinical benefits and side effects.
Community Join
5 / 1000+ resultscommunity if hmi-115 truly works, we can just get off off fin?
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
community Does anyone take bicalutamide for fphl? If so which dose
community Follicum releases some data from previous phase 2a trial
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
community 5 years – Fin, Min, Microneedle and then HT
A user's experience of using Fin, Min and Microneedle treatments to help thicken their hair before undergoing a Hair Transplant (HT) procedure. The conversation also includes discussion about the results post-HT, including pictures.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.